ABERA BIOSCIENCE AB (8WK) — Cash Flow-to-Debt Ratio
ABERA BIOSCIENCE AB (8WK) has a Cash Flow-to-Debt Ratio of -0.98x as of March 2026, meaning its operating cash flow of €-7.44 Million could theoretically repay -1% of its total liabilities (€7.57 Million) in one year. See how financially flexible is ABERA BIOSCIENCE AB to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ABERA BIOSCIENCE AB Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for ABERA BIOSCIENCE AB across 4 annual periods. For the full cash flow conversion analysis, see 8WK cash flow conversion.
Annual Cash Flow-to-Debt Ratio for ABERA BIOSCIENCE AB (2022–2025)
Year-by-year debt coverage analysis for ABERA BIOSCIENCE AB. Check cash flow quality index of ABERA BIOSCIENCE AB to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.35x | €-3.26 Million | €9.28 Million | ▼ -777.2% |
| 2024 | -0.04x | €-198.00K | €4.95 Million | ▲ +99.2% |
| 2023 | -4.80x | €-17.71 Million | €3.69 Million | ▲ +31.9% |
| 2022 | -7.05x | €-19.69 Million | €2.80 Million | — |